RELATED STUDY
Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders
Key Findings: The assigned medication was administered for 5 months. Significant improvement in spasticity and dystonia, sleep difficulties, pain severity, and QOL was observed in the total study cohort, regardless of treatment assignment
Type of Study: Human Trial
Study Sample Size: 25
Study Result: Positive
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Form of Administration: Not Applicable
Sub-Ratio: 1:20 and 1:6 (THC:CBD)
Dosage: Taken over 5 mo, two CBD enriched 5% oil formulations were compared: one with 0.25% THC( 20:1 group), the other with 0.83% THC (6:1 group)
Study Location(s): Israel
Year of Pub: 2018
Link to study